EPISODE · May 26, 2026 · 14 MIN
FDA Blocks Weight-Loss Drugs From Compounding Pharmacies as Supply Concerns Mount
from 1nessAgency Insights
The FDA's April 30, 2026 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list marks the most consequential regulatory shift in weight management marketing since these drugs entered the mainstream. For the clinics, telehealth platforms, and med sp
What this episode covers
The FDA's April 30, 2026 proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list marks the most consequential regulatory shift in weight management marketing since these drugs entered the mainstream. For the clinics, telehealth platforms, and med sp
NOW PLAYING
FDA Blocks Weight-Loss Drugs From Compounding Pharmacies as Supply Concerns Mount
No transcript for this episode yet
Similar Episodes
Apr 21, 2026 ·13m
Apr 19, 2026 ·16m
Apr 17, 2026 ·13m
Apr 13, 2026 ·11m
Apr 11, 2026 ·16m